

# Emma Hall

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/478231/emma-hall-publications-by-year.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

82 papers	10,177 citations	42 h-index	100 g-index
111 ext. papers	12,005 ext. citations	9.2 avg, IF	5.08 L-index

#	Paper	IF	Citations
82	VinCaP: a phase II trial of vinflunine in locally advanced and metastatic squamous carcinoma of the penis. <i>British Journal of Cancer</i> , <b>2021</b> ,	8.7	2
81	Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. <i>Cancer Discovery</i> , <b>2021</b> , 11, 2812-2827	24.4	15
80	Outcomes in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Chemotherapy Followed by (Chemo)radiotherapy in the BC2001 Trial. <i>European Urology</i> , <b>2021</b> , 79, 307-315	10.2	9
79	Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in -Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers. <i>Cancer Discovery</i> , <b>2021</b> , 11, 92-107	24.4	13
78	Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with - and Non--Mutant Cancers. <i>Cancer Discovery</i> , <b>2020</b> , 10, 1528-1543	24.4	37
77	CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer. <i>BJU International</i> , <b>2020</b> , 125, 817-826	5.6	12
76	Reply to Wei Liu, Xiaoping Liu, Sheng Li & Letter to the Editor, re: Robert A. Huddart, Emma Hall, Rebecca Lewis, et al. Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. <i>European Urology</i> , <b>2020</b> , 77, 151-157	10.2	
75	The 111 Study: A Single-arm, Phase 3 Trial Evaluating One Cycle of Bleomycin, Etoposide, and Cisplatin as Adjuvant Chemotherapy in High-risk, Stage 1 Nonseminomatous or Combined Germ Cell Tumours of the Testis. <i>European Urology</i> , <b>2020</b> , 77, 344-351	10.2	19
74	Patient-reported Quality of Life Outcomes in Patients Treated for Muscle-invasive Bladder Cancer with Radiotherapy ± Chemotherapy in the BC2001 Phase III Randomised Controlled Trial. <i>European Urology</i> , <b>2020</b> , 77, 260-268	10.2	26
73	Quality assuring "Plan of the day" selection in a multicentre adaptive bladder trial: Implementation of a pre-accrual IGRT guidance and assessment module. <i>Clinical and Translational Radiation Oncology</i> , <b>2019</b> , 19, 27-32	4.6	11
72	Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker. <i>Radiology</i> , <b>2019</b> , 293, 374-383	20.5	11
71	EP-1566 MR-guided online adaptive radiotherapy: First experience in the UK. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 133, S845	5.3	2
70	Methodology for tissue sample collection within a translational sub-study of the CHHiP trial (CRUK/06/016), a large randomised phase III trial in localised prostate cancer. <i>Clinical and Translational Radiation Oncology</i> , <b>2018</b> , 10, 1-6	4.6	0
69	The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004). <i>British Journal of Cancer</i> , <b>2017</b> , 116, 649-657	8.7	6
68	Clinical and patient-reported outcomes of SPARE - a randomised feasibility study of selective bladder preservation versus radical cystectomy. <i>BJU International</i> , <b>2017</b> , 120, 639-650	5.6	68
67	Prostate cancer and hypofractionation: reflections on recent randomised phase III clinical trial results. <i>Translational Andrology and Urology</i> , <b>2017</b> , 6, 134-136	2.3	3
66	Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. <i>Radiology</i> , <b>2017</b> , 283, 168-177	20.5	57

65	R-IDEAL: A Framework for Systematic Clinical Evaluation of Technical Innovations in Radiation Oncology. <i>Frontiers in Oncology</i> , <b>2017</b> , 7, 59	5.3	48
64	A phase I trial of selective PI3K inhibitor taselisib (tas) plus palbociclib (palb) with and without endocrine therapy incorporating pharmacodynamic (PD) studies in patients (pts) with advanced cancers.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2573-2573	2.2	1
63	TAX-TORC: A phase I trial of vistusertib (AZD2014) in combination with weekly paclitaxel with integrated pharmacodynamic (PD) and molecular characterization (MC) studies.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 2571-2571	2.2	
62	Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients. <i>Radiotherapy and Oncology</i> , <b>2016</b> , 121, 431-439	5.3	69
61	Clinical management and research priorities for high-risk prostate cancer in the UK: Meeting report of a multidisciplinary panel in conjunction with the NCRI Prostate Cancer Clinical Studies Localised Subgroup. <i>Journal of Clinical Urology</i> , <b>2016</b> , 9, 369-379	0.2	
60	DARS: a phase III randomised multicentre study of dysphagia- optimised intensity- modulated radiotherapy (Do-IMRT) versus standard intensity- modulated radiotherapy (S-IMRT) in head and neck cancer. <i>BMC Cancer</i> , <b>2016</b> , 16, 770	4.8	61
59	Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. <i>Lancet Oncology</i> , <b>2016</b> , 17, 1047-1060	21.7	587
58	Clinical development of new drug-radiotherapy combinations. <i>Nature Reviews Clinical Oncology</i> , <b>2016</b> , 13, 627-42	19.4	162
57	Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity. <i>British Journal of Cancer</i> , <b>2016</b> , 114, 1165-74	8.7	12
56	Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer. <i>EBioMedicine</i> , <b>2016</b> , 10, 150-63	8.8	50
55	Consensus Guidelines and Contouring Atlas for Pelvic Node Delineation in Prostate and Pelvic Node Intensity Modulated Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2015</b> , 92, 874-83	4	50
54	Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. <i>Lancet Oncology</i> , <b>2015</b> , 16, 1605-16	21.7	95
53	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1697-708	59.2	1345
52	Defining bowel dose volume constraints for bladder radiotherapy treatment planning. <i>Clinical Oncology</i> , <b>2015</b> , 27, 22-9	2.8	14
51	343 Translational phase I trial combining the AKT inhibitor AZD5363 (AZD) and PARP inhibitor Olaparib (Ola) in advanced cancer patients (pts). <i>European Journal of Cancer</i> , <b>2015</b> , 51, S68	7.5	2
50	Dynamic prediction methods in the BC2001 clinical trial. <i>Trials</i> , <b>2015</b> , 16,	2.8	78
49	Benefits and challenges of electronic data capture (EDC) systems versus paper case report forms. <i>Trials</i> , <b>2015</b> , 16,	2.8	5
48	Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. <i>European Journal of Cancer</i> , <b>2015</b> , 51, 271-81	7.5	80

47	Abstract CT323: Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose escalation design in advanced cancer patients <b>2015</b> ,		10
46	A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1. <i>Nature Genetics</i> , <b>2014</b> , 46, 891-4	36.3	92
45	Current attitudes of head and neck oncologists in the United Kingdom to induction chemotherapy for locally advanced head and neck cancer: a survey of centres participating in a national randomised controlled trial. <i>Oral Oncology</i> , <b>2014</b> , 50, 141-6	4.4	6
44	Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer. <i>European Urology</i> , <b>2014</b> , 66, 1148-56	10.2	45
43	A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity. <i>Radiotherapy and Oncology</i> , <b>2014</b> , 111, 178-85	5.3	102
42	Second cancer risk and mortality in men treated with radiotherapy for stage I seminoma. <i>British Journal of Cancer</i> , <b>2014</b> , 110, 256-63	8.7	59
41	Comparison of patient reported quality of life and impact of treatment side effects experienced with a taxane-containing regimen and standard anthracycline based chemotherapy for early breast cancer: 6 year results from the UK TACT trial (CRUK/01/001). <i>European Journal of Cancer</i> , <b>2014</b> , 50, 2375-89	7.5	27
40	Two-year and lifetime cost-effectiveness of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for head-and-neck cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2013</b> , 87, 683-9	4	21
39	Letter in response to the Wedlake et al. paper <b>Evaluating the efficacy of statins and ACE-inhibitors in reducing gastrointestinal toxicity in patients receiving radiotherapy for pelvic malignancies</b> <i>European Journal of Cancer</i> , <b>2013</b> , 49, 1783-6	7.5	1
38	Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004). <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2013</b> , 87, 261-9	4	77
37	Using a Bayesian approach with reverse philosophy to design clinical trials in rare diseases. <i>Trials</i> , <b>2013</b> , 14,	2.8	78
36	Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. <i>British Journal of Cancer</i> , <b>2013</b> , 109, 651-7	8.7	16
35	Re: Marco Roscigno, Maurizio Brausi, Axel Heidenreich, et al. Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer. <i>Eur Urol</i> 2011;60:776-83. <i>European Urology</i> , <b>2012</b> , 61, e16; author reply e17	10.2	
34	Time to define an international standard of postoperative care for resected upper urinary tract transitional cell carcinoma (TCC) - opening of the peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (POUT) Trial. <i>BJU International</i> , <b>2012</b> , 110, 919-21	5.6	29
33	Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial. <i>Lancet Oncology</i> , <b>2012</b> , 13, 43-54	21.7	253
32	Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. <i>Lancet Oncology</i> , <b>2012</b> , 13, 65-77	21.7	161
31	Novel approaches to improve the therapeutic index of head and neck radiotherapy: an analysis of data from the PARSPORT randomised phase III trial. <i>Radiotherapy and Oncology</i> , <b>2012</b> , 103, 82-7	5.3	45
30	Dosimetric explanations of fatigue in head and neck radiotherapy: an analysis from the PARSPORT Phase III trial. <i>Radiotherapy and Oncology</i> , <b>2012</b> , 104, 205-12	5.3	54

29	The Patient Deficit Model Overturned: a qualitative study of patients' perceptions of invitation to participate in a randomized controlled trial comparing selective bladder preservation against surgery in muscle invasive bladder cancer (SPARE, CRUK/07/011). <i>Trials</i> , <b>2012</b> , 13, 228	2.8	24
28	Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 1477-88	59.2	547
27	Intermittent androgen suppression for rising PSA level after radiotherapy. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 895-903	59.2	335
26	Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. <i>Lancet Oncology</i> , <b>2011</b> , 12, 127-36	21.7	1106
25	Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER Trial. <i>Journal of Cancer</i> , <b>2011</b> , 2, 374-7	4.5	43
24	Key issues in recruitment to randomised controlled trials with very different interventions: a qualitative investigation of recruitment to the SPARE trial (CRUK/07/011). <i>Trials</i> , <b>2011</b> , 12, 78	2.8	99
23	Boxing bladder cancer with COX-2-specific inhibition. <i>Cancer Prevention Research</i> , <b>2011</b> , 4, 1534-5	3.2	4
22	Life and death of spare (selective bladder preservation against radical excision): reflections on why the spare trial closed. <i>BJU International</i> , <b>2010</b> , 106, 753-5	5.6	78
21	Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)--a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen. <i>Annals of Oncology</i> , <b>2010</b> , 21, 498-505	10.3	31
20	430 Cross-sectional study of Quality of Life (QL) 6 years after start of treatment in the UK Taxotere as Adjuvant Chemotherapy Trial (TACT; CRUK01/001). <i>European Journal of Cancer, Supplement</i> , <b>2010</b> , 8, 184	1.6	1
19	Results of a 2 x 2 Phase III Randomized Trial of Synchronous Chemo-radiotherapy (CRT) Compared to Radiotherapy (RT) Alone and Standard vs. Reduced High Volume RT in Muscle Invasive Bladder Cancer (MIBC) (BC2001 CRUK/01/004). <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2010</b> , 78, S2-S3	4	5
18	Pre-trial quality assurance processes for an intensity-modulated radiation therapy (IMRT) trial: PARSPORT, a UK multicentre Phase III trial comparing conventional radiotherapy and parotid-sparing IMRT for locally advanced head and neck cancer. <i>British Journal of Radiology</i> , <b>2009</b> , 82, 585-84	3.4	37
17	Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial. <i>Lancet, The</i> , <b>2009</b> , 373, 1681-92	4.0	144
16	Randomized controlled trial of the effect of selenium supplementation on thyroid function in the elderly in the United Kingdom. <i>American Journal of Clinical Nutrition</i> , <b>2008</b> , 87, 370-8	7	83
15	First Toxicity Report of the BC2001 Trial: A Multicentre Phase III Randomised Trial of Radiotherapy with and without Synchronous Chemotherapy in Muscle Invasive Bladder Cancer ISCRTN No. 68324339, EUDRACT No. 2004-000164-26. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2008</b> , 72, S7	4	2
14	Human epidermal growth factor receptor 2 status correlates with lymph node involvement in patients with estrogen receptor (ER) negative, but with grade in those with ER-positive early-stage breast cancer suitable for cytotoxic chemotherapy. <i>Journal of Clinical Oncology</i> , <b>2007</b> , 25, 4423-30	2.2	59
13	Survival and safety of exemestane versus tamoxifen after 2-3 years tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. <i>Lancet, The</i> , <b>2007</b> , 369, 559-70	4.0	712
12	Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. <i>Lancet Oncology</i> , <b>2007</b> , 8, 119-27	21.7	348

11	Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer. <i>Journal of Clinical Oncology</i> , <b>2006</b> , 24, 910-7	2.2	159
10	Double-blind, placebo-controlled, randomised phase II trial of IH636 grape seed proanthocyanidin extract (GSPE) in patients with radiation-induced breast induration. <i>Radiotherapy and Oncology</i> , <b>2006</b> , 79, 45-51	5.3	40
9	Impact of selenium on mood and quality of life: a randomized, controlled trial. <i>Biological Psychiatry</i> , <b>2006</b> , 59, 147-54	7.9	79
8	Phase II study of vitamin E and pentoxifylline in patients with late side effects of pelvic radiotherapy. <i>Radiotherapy and Oncology</i> , <b>2005</b> , 75, 334-41	5.3	44
7	Persistence of bone marrow micrometastases in patients receiving adjuvant therapy for breast cancer: results at 4 years. <i>International Journal of Cancer</i> , <b>2005</b> , 114, 94-100	7.5	55
6	A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. <i>New England Journal of Medicine</i> , <b>2004</b> , 350, 1081-92	59.2	1500
5	Non-randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema and tissue fibrosis after radiotherapy for early breast cancer. <i>Radiotherapy and Oncology</i> , <b>2004</b> , 70, 217-24	5.3	66
4	Double-blind placebo-controlled randomised trial of vitamin E and pentoxifylline in patients with chronic arm lymphoedema and fibrosis after surgery and radiotherapy for breast cancer. <i>Radiotherapy and Oncology</i> , <b>2004</b> , 73, 133-9	5.3	83
3	Aromatase inhibitors as adjuvant therapies in patients with breast cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2003</b> , 86, 309-11	5.1	16
2	Alcohol and coronary heart disease reduction among British doctors: confounding or causality?. <i>European Heart Journal</i> , <b>1997</b> , 18, 23-5	9.5	19
1	Mortality in relation to consumption of alcohol: 13 years observations on male British doctors. <i>BMJ: British Medical Journal</i> , <b>1994</b> , 309, 911-8		409